Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?

Authors :: Cremolini C
Loupakis F
Ruzzo A
Perrone G
Rulli E
Vincenzi B
Tonini G
Graziano F
Muda AO
Falcone A
Source :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 Apr 10; Vol. 28 (11), pp. e173-4; author reply e175-6. Date of Electronic Publication: 2010 Feb 22.
Publication Year :: 2010

Subjects :: Antibodies, Monoclonal, Humanized
Cetuximab
Colorectal Neoplasms metabolism
ErbB Receptors antagonists & inhibitors
ErbB Receptors metabolism
Humans
Immunoenzyme Techniques
Prognosis
Proto-Oncogene Proteins genetics
Proto-Oncogene Proteins B-raf genetics
Proto-Oncogene Proteins p21(ras)
Receptors, Androgen metabolism
Retrospective Studies
ras Proteins genetics
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Colorectal Neoplasms drug therapy
Colorectal Neoplasms genetics
Mutation genetics

Language :: English
ISSN :: 1527-7755
Volume :: 28
Issue :: 11
Database :: MEDLINE
Journal :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Type :: Editorial & Opinion
Accession number :: 20177018
Full Text :: https://doi.org/10.1200/JCO.2009.26.6148

Full Text Access

Tools